Autoimmune encephalitides have been recognized in association with antibodies targeting neuronal surface antigen antibodies [NSAbs].
GLYCINE RECEPTOR ANTIBODIES IN 2 CASES OF NEW, ADULT-ONSET EPILEPSY
Autoimmune encephalitides have been recognized in association with antibodies targeting neuronal surface antigen antibodies [NSAbs] . 1 Glycine receptors (GlyRs) are fundamental in motor neuron excitability, and antibodies against GlyRa1 (GlyR-Abs) were identified in a case of progressive encephalomyelitis with rigidity and myoclonus (PERM) 2 and subsequently in other cases related to the stiff person syndrome spectrum. 3 GlyRs are expressed mainly in the spine and brainstem but also in the hippocampus. 4 Here we report 2 patients with subacute onset of refractory temporal lobe seizures associated with behavioral changes and memory deficits whose sera were positive for GlyR-Abs.
Case reports. Patient 1. A 25-year-old man presented with a generalized convulsive status epilepticus (GCSE). Apathy and anxiety were noted over a few days. Status epilepticus was controlled with propofol. Vital signs, neurologic examination, routine blood tests, CSF analysis, and brain MRI were normal. Postictal EEG disclosed diffuse slow abnormalities. On day 2, GCSE recurred and he was transferred to the intensive care unit (ICU). Over the following days, when sedation was withdrawn, seizures continued despite IV phenytoin and levetiracetam. An EEG performed on day 7 showed an ictal discharge over right temporal leads, clinically associated with a convulsive generalized seizure (figure, A). Screening for pathogenic microorganisms, systemic autoimmunity, serum "onconeural," GAD65, NMDAR, AMPAR, GABAbR, and voltagegated potassium channel (VGKC)-complex autoantibodies was negative. Brain MRI was uninformative. On day 17, IV steroid (methylprednisolone 1 g/d for 7 days) was started, and 3 days later seizure frequency declined. Off sedation, the patient had only sporadic focal seizures. However, when steroids were tapered, status epilepticus reappeared. IV immunoglobulin (IVIg) (0.4 g/kg/d for 5 days) was started with marked improvement, and on day 40 he was discharged from the ICU. Seizures were controlled with a combination of phenobarbital, phenytoin, and zonisamide. EEG showed diffuse slow waves while brain MRI revealed a T2-weighted hyperintensity with mild swelling of right hippocampus, likely due to local edema induced by status epilepticus (figure, B). A wider autoantibody screening with a live cell-based assay subsequently showed GlyR-Ab positivity in serum; CSF was not available for further testing. The patient was transferred to the rehabilitation department and discharged after 8 weeks. By telephone interview 5 months after discharge, he was seizure-free on the same antiepileptic drug (AED) combination.
Patient 2. A 41-year-old woman presented with a 3-month history of daily short-lasting (seconds) episodes characterized by abdominal pain followed by lightheadedness, nausea, goose bumps, and sensation of uncomfortable breathing. In the same period she started complaining of short-term memory difficulty. EEG revealed ictal discharges over right temporal leads (figure, C). 3T brain MRI showed a mild asymmetry of hippocampal volume (right 5.80 mL; left 5.24 mL; normal value 4.48-6.41 mL) with no different signal intensities on fluid-attenuated inversion recovery and T2-weighted images. She was given different AEDs (oxcarbazepine, lacosamide, valproate) without benefit. Four months later she was admitted because of persisting seizures with new onset of sudden spasms involving the whole body. Neurologic examination revealed mild cerebellar ataxia. Neuropsychological examination showed severe impairment of attention as well as shortand long-term verbal memory, moderate anxiety, and depression. Polygraphy disclosed sudden diffuse spasms, both spontaneous and induced by eye-opening or intermittent photic stimulation, with no EEG correlate ( figure, D) . CSF analysis was normal; oligoclonal bands were absent. Neoplastic markers, systemic autoimmunity, serum "onconeural"and GAD65, and serum and CSF NMDAR, AMPAR, GABAbR, and VGKCcomplex autoantibodies were negative. GlyR-Abs were positive in serum but not detected in CSF. She was given IVIg 0.4 g/kg/d for 5 days with disappearance of the spasms and discharged home on oxcarbazepine and valproate. Over the following year, seizure frequency decreased but memory complaints persisted. Brain MRI showed no change. IV methylprednisolone 0.5 g/d for 5 days followed by oral prednisone was given. Due to inefficacy of steroid treatment (persistence of weekly seizures as well as severe short-and long-term verbal memory impairment), prednisone was gradually tapered off over a period of 3 months. The patient is currently receiving only the abovementioned antiepileptic treatment and refuses further trial with IVIg.
Discussion. The clinical picture of our 2 patients is in keeping with limbic encephalitis (LE). Patient 2 also displayed spontaneous and stimulus-sensitive spasms suggesting rhomboencephalitis and the diagnosis of PERM. It is thought that early diagnosis of LE should be considered in patients with multiple mesiotemporal seizures even in the absence of typical MRI abnormalities. 5 The possibility of an NSAbassociated autoimmune encephalitis 1 justified a trial of immunomodulatory treatment in both patients and was further supported by the finding of serum GlyRAbs. Immunomodulation was effective in controlling symptoms in patient 1. In patient 2 IVIg provoked disappearance of spasms but only a mild reduction of seizure frequency and had no effect on attention and memory impairment; steroids were ineffective.
To our knowledge, seizures were reported in 1 patient with GlyR-Ab/PERM and another had seizures with hippocampal inflammatory involvement, but NMDAR-Ab coexisted. 6 Of course, we cannot exclude the possibility that other antibodies were present and could explain hippocampal involvement in our patients. The antibody assay employed measured Ab to the a1 subunit, but these antibodies often crossreact with hippocampal GlyRs a2 and 3 subunits. 6 Of note, GlyR expression is altered in patients with temporal lobe epilepsy 4 and GlyR-Abs were identified in 3% of a large cohort of patients with epilepsy. 7 We suggest that screening for NSAb could include GlyR-Ab in patients with autoimmune LE with seizures. 
